Rare Adverse Events Related to Nivolumab, an Immune Checkpoint Inhibitor: A Case Series

Nagapratap Ganta 1, Dina Alnabwani 1, Shawn Keating 1, Vraj Patel 1, Veera Jayasree Latha Bommu 1, 2, Rand Dawoud 3, Pramil Cheriyath 1

1. Internal Medicine, Hackensack Meridian Ocean Medical Center, Brick, USA 2. Internal Medicine, Government Medical College and Hospital, Kadapa, IND 3. Medical School, The Hashemite University, Amman, JOR

Corresponding author: Vraj Patel, vrajpatel123@gmail.com

Abstract

Immune checkpoint inhibitors are a novel class of immunotherapy drugs that have improved the prognosis of melanoma, renal cell carcinoma, non-small cell lung cancer, urothelial carcinoma, and various other solid tumors. Nivolumab is an immune checkpoint inhibitor that acts by inhibiting programmed death. Its use is associated with significant immune-related adverse events, such as pneumonitis, thyroiditis, hepatitis, pruritus, vitiligo, and diarrhea. However, adrenal insufficiency and checkpoint inhibitor-related autoimmune diabetes mellitus are extremely rare adverse events related to nivolumab treatment. Here, we are highlighting cases of adrenal insufficiency and diabetes insipidus as a result of nivolumab. These rare adverse events in our case series are to raise awareness that this medication also may be the cause for this illness among oncologists, endocrinologists, internists, and other clinicians.

Introduction

With recent advancements in immunology and cancer biology, new classes of immunomodulatory therapies have been developed to aid tumor management [1]. Immune checkpoint inhibitors (ICIs) have improved the prognosis of melanoma, renal cell carcinoma, non-small cell lung cancer, urothelial carcinoma, and other solid tumor types. Ipilimumab (cytotoxic T-lymphocyte-associated antigen 4: CTLA-4 inhibitor), nivolumab, and pembrolizumab (programmed death: PD-1 inhibitors), atezolizumab, avelumab, and durvalumab are some of the medications in this class (programmed death-ligand: PD-L1 inhibitors) that have been approved.

Despite their key role in regulating the immune response by either stimulating or inhibiting the pathways that modulate T-cell function, ICIs are associated with serious immune-related adverse events (irAEs), which can affect any organ and are difficult to diagnose and treat [2]. Rashes, pruritus, vitiligo, thyroiditis, diarrhea, hepatitis, and pneumonitis are among the most common immune-related side effects of PD-1 inhibitors. Nivolumab is usually associated with pneumonitis and thyroid dysfunction and only rarely causes adrenal insufficiency (AI) or elevated blood sugar levels (0.7% of patients in randomized clinical trials) [3].

Here, we report a case series of nivolumab-induced AI and diabetes mellitus in a 79-year-old male patient and a 62-year-old female patient, respectively.

Case Presentation

Case summary 1

A 79-year-old male presented to the emergency department with complaints of dizziness, myalgia, and nausea associated with a decreased appetite for 4 days prior to presentation. He denied any associated fever, vomiting, abdominal pain, trauma, diplopia, or numbness. He has a history of hypertension, benign prostatic hyperplasia, malignant melanoma of the buccal mucosa, and rectal cancer. He was currently receiving immunotherapy consisting of nivolumab (Opdivo®, Bristol-Myers Squibb Company, New York, USA) every 4 weeks for rectal cancer. He developed a progressive generalized rash over the month prior to receiving immunotherapy consisting of nivolumab (Opdivo®, Bristol-Myers Squibb Company, New York, USA) every 4 weeks for rectal cancer. He developed a progressive generalized rash over the month prior to presentation for which he was evaluated by a dermatologist who diagnosed him with atopic dermatitis.

The patient’s vital signs on presentation were as follows: temperature, 98.1°F; pulse rate, 83/min; blood pressure, 128/71 mmHg; and respiratory rate, 18 breaths per minute with 99% SpO2 on room air. On physical examination, the patient was alert and oriented to place, person, and time, and slight edema in the lower extremities was observed. His laboratory results were as follows: sodium, 122 mmol/L; potassium, 4.4 mmol/L; chloride, 91 mmol/L; blood glucose, 88 mg/dL; and blood urea nitrogen, 8 mg/dL. The calculated serum osmolality for the patient was 251.75 mOsm/L. His baseline serum sodium typically ranges between

How to cite this article

Ganta N, Alnabwani D, Keating S, et al. (February 09, 2022) Rare Adverse Events Related to Nivolumab, an Immune Checkpoint Inhibitor: A Case Series. Cureus 14(2): e22070. DOI 10.7759/cureus.22070
A systematic review and meta-analysis published in 2018 included 38 randomized trials with 7,551 patients.

The common drugs causing PAI are warfarin, phenobarbital, phenytoin, rifampin, ketoconazole, fluconazole, and production.

The hypothalamic-pituitary axis responds to lower serum cortisol levels by increasing ACTH, which results in increased cortisol production. The adrenal cortex is stimulated to release glucocorticoids and mineralocorticoids as a response to this increased ACTH production. This scenario is potentially life-threatening due to the vital role that glucocorticoids and mineralocorticoids play in salt, fluid, and energy balance.

The inability of the adrenal gland cortex to produce sufficient levels of glucocorticoids and/or mineralocorticoids is known as primary adrenal insufficiency (PAI). This scenario is potentially life-threatening due to the vital role that glucocorticoids and mineralocorticoids play in salt, fluid, and energy balance. The hypothalamic-pituitary axis responds to lower serum cortisol levels by increasing ACTH production [2]. Some of the causes of PAI are autoimmune, infectious, genetic, metastasis, drug-induced. The common drugs causing PAI are warfarin, phenobarbital, phenytoin, rifampin, ketoconazole, fluconazole [5]. PAI is considered extremely rare among irAEs, but it may be underdiagnosed.

A systematic review and meta-analysis published in 2018 included 38 randomized trials with 7,551 patients.
and reported the incidence of endocrinopathies caused by ICIs. According to that study, PAI of any grade was documented in 43 out of 5,831 individuals (0.7%), although only 0.2% had grade 3 or above. AI was more common in patients who received a combination of ICIs (11 of 262, 4.2%) [6]. Wang et al. [7] analyzed fatal toxicity data from a global adverse drug reaction database (VigiLyze, VigiBase) and found 614 fatal irAEs; adrenal toxicity was the cause of death in eight patients treated with ipilimumab and six patients treated with anti- PD-1/PD-L1 drugs [8].

AI can manifest in various ways, ranging from asymptomatic test changes to a significant medical emergency. Fatigue, dizziness, orthostatic symptoms, anorexia, weight loss, and stomach discomfort are the most common clinical symptoms, just as they are with AI due to any other cause. Refractory hypotension, altered state of consciousness, widespread weakness, stomach discomfort, shock, and, in severe cases, death are common symptoms. Hyponatremia and hyperkalemia are common laboratory abnormalities, but hypoglycemia and hypercalcemia are less common [2]. Early morning cortisol, ACTH, and ACTH stimulation tests are all laboratory tests to consider, as they could show the degree of AI. Additional tests, such as those that determine renin and aldosterone levels after ACTH stimulation, can help evaluate the severity of the mineralocorticoid deficit [2].

PD-L1 and PD-L2 were recently discovered to be expressed in non-immune tissues in mice, including the anterior and intermediate portion of the pituitary gland, extending to the ventral side of the pituitary stalk, but not the posterior pituitary gland [9]. This shows that a specific lesion could occur that exclusively affects certain anterior pituitary cells, such as those that produce ACTH. To understand the pathophysiology of pituitary-specific toxicity associated with PD-1 inhibitors, it is crucial to understand how PD-1 is expressed in the pituitary [1].

Nivolumab-induced autoimmune diabetes mellitus is another rare adverse event. Type I diabetes mellitus (T1DM) is diagnosed by the occurrence of hyperglycemia with evidence of autoimmunity and insulin insufficiency; 90% of patients test positive for islet autoantibodies at some point during treatment [10]. Patients with drug reactions with eosinophilia and systemic symptoms (DRESS) are at risk for autoimmune disorders such as T1DM, thyroiditis, and systemic lupus erythematosus (SLE). Other drugs causing T1DM are carbamazepine, mesoxetine, minocycline, allopurinol, and dapsone [11].

The best predictor of the development of checkpoint inhibitor-related autoimmune diabetes (CIADM) is exposure to ICi therapy involving the PD-1/PD-L1 axis. According to pharmacovigilance data from the FDA Adverse Events Reporting System, adverse events are highest after the administration of anti-CTLA-4 plus either anti-PD-1 or anti-PD-L1 therapy (2.60%), followed by anti-PD-1 therapy alone (1.18%), anti-PD-L1 therapy alone (0.73%), and anti-CTLA-4 therapy alone (0.33%) [12].

Recent research has revealed that the autoimmune destruction of the pancreas is caused by a flaw in the beta-cell insulin gene sequence. This event, which is most noticeable in cancer patients who receive immunotherapy treatment, demonstrates that previously working beta cells begin to express non-functional proteins, a characteristic trait of cancer cells. This triggers the usual antitumor reaction of the immune system against these pancreatic cells, which could explain why some cancer patients develop T1DM after receiving immunotherapy [13]. Anti-PD-1-related T1DM cases have yielded mixed results in terms of the prevalence of diabetes-related autoantibodies after the onset of T1DM. Hughes et al. reported that, after receiving anti-PD1 medication, five cases exhibited new-onset insulin-dependent diabetes. After the onset of T1DM, three of these five patients were positive for at least one diabetes-related autoantibody [14].

The number of patients who will receive anti-PD1 therapy will rapidly increase as its approval expands in the upcoming years, as will the frequency of the autoimmune side effects. Medical oncologists should be aware of the risk of anti-PD1 therapy-induced autoimmune disease and advise their patients to report any symptoms as soon as possible, as this constitutes a medical emergency. Treatment of CIADM is similar to treatment of T1DM and includes insulin regimens according to the patient’s serum glucose levels. Patients should be treated early to prevent life-threatening complications such as diabetic ketoacidosis (DKA).

Today, recognition of irAEs in cancer patients is critical, as individuals may present without conventional symptoms or, as in our case, with isolated endocrine abnormalities. Since irAEs are classified as hazardous adverse events, most recommend stopping immune checkpoint inhibitor treatment, but this remains debatable. In most individuals with AI, high-dose glucocorticoid treatment is also recommended, while an insulin regimen is recommended for T1DM [1].

Conclusions
Advances in immuno-oncology have resulted in the development of successful treatments consisting of novel immune response-modulating drugs. irAEs are common when ICIs are frequently used. If not detected and treated early, AI or CIADM can have very catastrophic consequences. Therefore, it is critical to pay close attention to these possibly fatal unusual consequences and maintain a high level of clinical suspicion. Lifelong glucocorticoid treatment is the treatment of choice for PAI to restore the hypothalamic-pituitary-adrenal axis, while insulin regimens are recommended for CIADM. Long-term monitoring is required as is
patient education so that symptoms are identified; proper counseling is also necessary to control and increase awareness of potential side effects.

Additional Information

Disclosures

Human subjects: Consent was obtained or waived by all participants in this study. Conflicts of interest: In compliance with the ICMJE uniform disclosure form, all authors declare the following: Payment/services info: All authors have declared that no financial support was received from any organization for the submitted work. Financial relationships: All authors have declared that they have no financial relationships at present or within the previous three years with any organizations that might have an interest in the submitted work. Other relationships: All authors have declared that there are no other relationships or activities that could appear to have influenced the submitted work.

References

1. Neril R, Lorton J, Zonszein J: Nivolumab-induced isolated adrenal insufficiency: a case report. AACE Clin Case Rep. 2017, 3:210-2. 10.4158/ep161491.cr
2. Salinas C, Renner A, Rojas C, Samstani S, Burotto M: Primary adrenal insufficiency during immune checkpoint inhibitor treatment: case reports and review of the literature. Case Rep Oncol. 2020, 13:e621-6. 10.1159/000507662
3. Rai M, Go M: Nivolumab induced adrenal insufficiency: rare side-effect of a new anti-cancer therapy - immune-checkpoint inhibitors. Cureus. 2020, 12:e7625. 10.7759/cureus.7625
4. Kagoshima H, Hori R, Kojima T, Okanooue Y, Fujimura S, Taguchi A, Shoji K: Adrenal insufficiency following nivolumab therapy in patients with recurrent or metastatic head and neck cancer. Auris Nasus Larynx. 2020, 47:509-13. 10.1016/j.anl.2019.05.009
5. Nicolaides NC, Chrousos GP, Charmandari E: Adrenal Insufficiency [Updated 2017 Oct 14]. Endotext [Internet]. Feingold KR, Anawalt B, Boyce A, et al. (ed): MDText.com, Inc., South Dartmouth; 2000.
6. Brahmer JR, Lacchetti C, Thompson JA: Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: American Society of Clinical Oncology Clinical Practice guideline summary. J Oncol Pract. 2018, 14:247-9. 10.1200/JOP.18.00005
7. Wang DY, Salem JE, Cohen JV, et al.: Fatal toxic effects associated with immune checkpoint inhibitors: a systematic review and meta-analysis. JAMA Oncol. 2018, 4:1721-8. 10.1001/jamaoncol.2018.3923
8. Yang JC, Hughes M, Kammula U, et al.: Ipilimumab (anti-CTLA4 antibody) causes regression of metastatic renal cell cancer associated with enteritis and hypophysitis. J Immunother. 2007, 30:825-30. 10.1097/CJI.0b013e318156e47e
9. Zhao Y, Bian G, Yu C, et al.: Cross-reactivity of anti-programmed death ligand 2 polyclonal antibody in mouse tissues. Sci China Life Sci. 2012, 55:940-7. 10.1007/s11427-012-4379-7
10. Wu L, Tsang VH, Saxon SC, et al.: Unravelling checkpoint inhibitor associated autoimmune diabetes: from bench to bedside. Front Endocrinol (Lausanne). 2021, 12:764158. 10.3389/fendo.2021.764158
11. Zhu B, Wu J, Chen G, Yang Y, Yi C: Fulminant type 1 diabetes mellitus caused by drug reaction with eosinophilia and systemic symptoms (DRESS): a case report and review of the literature. Front Endocrinol (Lausanne). 2019, 10:474. 10.3389/fendo.2019.00474
12. Liu J, Zhou H, Zhang Y, Fang W, Yang Y, Huang Y, Zhang L: Reporting of immune checkpoint inhibitor therapy-associated diabetes, 2015-2019. Diabetes Care. 2020, 43:e79-80. 10.2337/dc20-0459
13. Baroud S, Mirza L: New-onset type 1 diabetes mellitus after treatment with nivolumab for melanoma . Cureus. 2021, 13:e18679. 10.7759/cureus.18679
14. Hughes J, Vadattu N, Szoln M, Gettinger S, Kluger H, Lupsa B, Herold KC: Precipitation of autoimmune diabetes with anti-PD-1 immunotherapy. Diabetes Care. 2015, 38:e55-7. 10.2337/dc14-2549